PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy

Phase 3

Recruiting

• Conditions: Lymphoma
• Interventions: Drug: CHOP; Drug: CHOP Plus Lanzoprazole; Drug: CHOP Plus Famotidine

• Registration Number: NCT03647072
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.

Detailed Description

The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump Inhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma to compare the difference in efficacy.

Study Timeline

• Status Verified: 2018-08
• Study Start: 2018-08-01
• Study First Submitted: 2018-08-23
• Study First Submitted QC: 2018-08-23
• Last Update Submitted: 2018-08-23
• Study First Posted: 2018-08-27
• Last Update Posted: 2018-08-27
• Primary Completion: 2027-10
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• DLBCL Lymphoma subtype --No comorbid disease

Exclusion Criteria

• Pregnancy
• Peptic ulcer
• Severe cardiac disease
• Osteoporosis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CHOP	CHOP	CHOP only
CHOP Plus Lanzoprazole	CHOP Plus Lanzoprazole	CHOP Plus Lanzoprazole 60 mg
CHOP Plus Famotidine	CHOP Plus Famotidine	CHOP Plus Famotidine 40 mg

Primary Outcome Measures

Name	Time	Method
Number of patients eith radiological and clinical improvement	6 months	Number of patients eith radiological and clinical improvement after cycles of chemotherapy

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Cairo, Egypt